Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DS-2243a |
| Synonyms | |
| Therapy Description |
DS-2243a is a bispecific T-cell engager targeting NY-ESO-1 presented by the HLA-A*02 complex on tumor cells and an undisclosed antigen on cytotoxic T-lymphocytes, which redirects cytotoxic T-lymphocytes towards tumor cells expressing NY-ESO-1, potentially resulting in increased tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DS-2243a | DS 2243a|DS2243a | DS-2243a is a bispecific T-cell engager targeting NY-ESO-1 presented by the HLA-A*02 complex on tumor cells and an undisclosed antigen on cytotoxic T-lymphocytes, which redirects cytotoxic T-lymphocytes towards tumor cells expressing NY-ESO-1, potentially resulting in increased tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06644755 | Phase I | DS-2243a | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | Recruiting | USA | NLD | FRA | BEL | 1 |